HUP0103113A2 - NOS inhibitorokat tartalmazó gyógyászati készítmények - Google Patents
NOS inhibitorokat tartalmazó gyógyászati készítményekInfo
- Publication number
- HUP0103113A2 HUP0103113A2 HU0103113A HUP0103113A HUP0103113A2 HU P0103113 A2 HUP0103113 A2 HU P0103113A2 HU 0103113 A HU0103113 A HU 0103113A HU P0103113 A HUP0103113 A HU P0103113A HU P0103113 A2 HUP0103113 A2 HU P0103113A2
- Authority
- HU
- Hungary
- Prior art keywords
- ring
- general formula
- headache
- atom
- oxygen atom
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 206010019233 Headaches Diseases 0.000 abstract 2
- 208000002193 Pain Diseases 0.000 abstract 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 abstract 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 231100000869 headache Toxicity 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 2
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 208000005298 acute pain Diseases 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical group C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
A találmány tárgyát gyógyászati készítmények képezik, amelyek NOSgátló hatású (I), (II), (III), (IV), (V) vagy (VI) általános képletűvegyületet vagy ennek gyógyászatilag megfelelő sóját, továbbá valamelyegyéb gyógyászati hatóanyagot tartalmaznak. Az (I)-(VI) általánosképletű vegyületek alkalmazhatók gyulladásos rendellenességek,krónikus vagy akut fájdalom, migrén, féloldali fejfájás és egyébérrendszeri eredetű fejfájás kezelésére. Az (I)-(VI) általánosképletben a szubsztituensek jelentése sokféle, így például az (I)általános képletben az A gyűrű jelentése az A gyűrű jelentése 5-7 tagútelített vagy telítetlen kondenzált gyűrű, amelyben 0-2 gyűrűtagkéntheteroatomok vannak jelen egymástól függetlenül nitrogénatom,oxigénatom és kénatom közül választva, azzal a feltétellel, hogy kétegymással szomszédos gyűrűtagként nem állhat heteroatom; X jelentéseoxigénatom vagy vegyértékkötés, n értéke 2-6-ig terjedő egész szám,továbbá R1 és R2 jelentése többek között egymástól függetlenül adottesetben szubsztituált alkil-, aril-, tetrahidronaftalin ésaralkilcsoport vagy R1 és R2 jelentése a nitrogénatommal együtt,amelyhez kapcsolódnak, piperazin-, azetidin-, piperidin- vagypirrolidingyűrű vagy azabiciklusos csoport. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9615298P | 1998-08-11 | 1998-08-11 | |
| PCT/IB1999/001389 WO2000009130A2 (en) | 1998-08-11 | 1999-08-05 | New pharmaceutical uses for nos inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0103113A2 true HUP0103113A2 (hu) | 2002-01-28 |
| HUP0103113A3 HUP0103113A3 (en) | 2002-02-28 |
Family
ID=22255853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0103113A HUP0103113A3 (en) | 1998-08-11 | 1999-08-05 | New pharmaceutical compositions uses for nos inhibitors |
Country Status (37)
| Country | Link |
|---|---|
| US (1) | US20020151572A1 (hu) |
| EP (1) | EP1109556A2 (hu) |
| JP (1) | JP2002522498A (hu) |
| KR (1) | KR20010085364A (hu) |
| CN (1) | CN1323211A (hu) |
| AP (1) | AP2001002067A0 (hu) |
| AR (1) | AR020009A1 (hu) |
| AU (1) | AU749439B2 (hu) |
| BR (1) | BR9912906A (hu) |
| CA (1) | CA2340200A1 (hu) |
| CO (1) | CO5130011A1 (hu) |
| CR (1) | CR6302A (hu) |
| CZ (1) | CZ2001486A3 (hu) |
| DZ (1) | DZ2867A1 (hu) |
| EA (1) | EA200100125A1 (hu) |
| EE (1) | EE200100084A (hu) |
| GE (1) | GEP20043252B (hu) |
| GT (1) | GT199900127A (hu) |
| HK (1) | HK1041819A1 (hu) |
| HR (1) | HRP20010099A2 (hu) |
| HU (1) | HUP0103113A3 (hu) |
| ID (1) | ID28227A (hu) |
| IL (1) | IL141031A0 (hu) |
| IS (1) | IS5814A (hu) |
| MA (1) | MA26670A1 (hu) |
| NO (1) | NO20010685L (hu) |
| NZ (1) | NZ509298A (hu) |
| OA (1) | OA11595A (hu) |
| PA (1) | PA8479801A1 (hu) |
| PE (1) | PE20001025A1 (hu) |
| PL (1) | PL346842A1 (hu) |
| SK (1) | SK1702001A3 (hu) |
| SV (1) | SV1999000121A (hu) |
| TN (1) | TNSN99154A1 (hu) |
| TR (3) | TR200100434T2 (hu) |
| WO (1) | WO2000009130A2 (hu) |
| YU (1) | YU9601A (hu) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010049379A1 (en) | 1997-08-27 | 2001-12-06 | Lowe John Adams | 2-aminopyridines containing fused ring substituents |
| AU2001235284A1 (en) | 2000-02-22 | 2001-09-03 | Cellegy Canada Inc. | Methods and compositions for improving sleep |
| US20030219494A1 (en) * | 2002-03-20 | 2003-11-27 | Smith Maree Therese | Compositions and methods of using them |
| WO2005007627A1 (ja) * | 2003-07-18 | 2005-01-27 | Nihon Nohyaku Co., Ltd. | フェニルピリジン誘導体、その中間体及びこれを有効成分とする除草剤 |
| US9120750B2 (en) | 2013-03-07 | 2015-09-01 | Northwestern University | 2-Aminopyridine-based selective neuronal nitric oxide synthase inhibitors |
| US9951014B2 (en) | 2014-11-04 | 2018-04-24 | Northwestern University | Mammalian and bacterial nitric oxide synthase inhibitors |
| US10759791B2 (en) | 2014-11-04 | 2020-09-01 | Northwestern University | Mammalian and bacterial nitric oxide synthase inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2214604T3 (es) * | 1996-03-29 | 2004-09-16 | Pfizer Inc. | Derivados de la 6-fenilpiridil-2-amina. |
| HN1997000027A (es) * | 1996-12-06 | 1997-06-05 | Pfizer Prod Inc | Derivados de 6-fenil piridil - 2 amina |
| CN1246848A (zh) * | 1997-02-10 | 2000-03-08 | 辉瑞产品公司 | 2－氨基－6－(2－取代的－4－苯氧基)取代的吡啶类化合物 |
| HN1998000118A (es) * | 1997-08-27 | 1999-02-09 | Pfizer Prod Inc | 2 - aminopiridinas que contienen sustituyentes de anillos condensados. |
| HN1998000125A (es) * | 1997-08-28 | 1999-02-09 | Pfizer Prod Inc | 2-aminopiridinas con sustituyentes alcoxi ramificados |
| SE9703693D0 (sv) * | 1997-10-10 | 1997-10-10 | Astra Pharma Prod | Novel combination |
-
1999
- 1999-08-05 YU YU9601A patent/YU9601A/sh unknown
- 1999-08-05 WO PCT/IB1999/001389 patent/WO2000009130A2/en not_active Application Discontinuation
- 1999-08-05 EA EA200100125A patent/EA200100125A1/ru unknown
- 1999-08-05 NZ NZ509298A patent/NZ509298A/en unknown
- 1999-08-05 TR TR2001/00434T patent/TR200100434T2/xx unknown
- 1999-08-05 TR TR2004/01803T patent/TR200401803T2/xx unknown
- 1999-08-05 KR KR1020017001788A patent/KR20010085364A/ko not_active Application Discontinuation
- 1999-08-05 PL PL99346842A patent/PL346842A1/xx not_active Application Discontinuation
- 1999-08-05 TR TR2001/03661T patent/TR200103661T2/xx unknown
- 1999-08-05 AP APAP/P/2001/002067A patent/AP2001002067A0/en unknown
- 1999-08-05 CA CA002340200A patent/CA2340200A1/en not_active Abandoned
- 1999-08-05 BR BR9912906-0A patent/BR9912906A/pt not_active IP Right Cessation
- 1999-08-05 ID IDW20010317A patent/ID28227A/id unknown
- 1999-08-05 EP EP99933077A patent/EP1109556A2/en not_active Withdrawn
- 1999-08-05 IL IL14103199A patent/IL141031A0/xx unknown
- 1999-08-05 AU AU49248/99A patent/AU749439B2/en not_active Ceased
- 1999-08-05 CZ CZ2001486A patent/CZ2001486A3/cs unknown
- 1999-08-05 CN CN99811907A patent/CN1323211A/zh active Pending
- 1999-08-05 OA OA1200100036A patent/OA11595A/en unknown
- 1999-08-05 JP JP2000564633A patent/JP2002522498A/ja active Pending
- 1999-08-05 SK SK170-2001A patent/SK1702001A3/sk unknown
- 1999-08-05 GE GEAP19995742A patent/GEP20043252B/en unknown
- 1999-08-05 HU HU0103113A patent/HUP0103113A3/hu unknown
- 1999-08-05 EE EEP200100084A patent/EE200100084A/xx unknown
- 1999-08-06 PA PA19998479801A patent/PA8479801A1/es unknown
- 1999-08-09 GT GT199900127A patent/GT199900127A/es unknown
- 1999-08-09 PE PE1999000801A patent/PE20001025A1/es not_active Application Discontinuation
- 1999-08-10 DZ DZ990167A patent/DZ2867A1/xx active
- 1999-08-10 AR ARP990103995A patent/AR020009A1/es unknown
- 1999-08-10 SV SV1999000121A patent/SV1999000121A/es not_active Application Discontinuation
- 1999-08-10 TN TNTNSN99154A patent/TNSN99154A1/fr unknown
- 1999-08-10 MA MA25724A patent/MA26670A1/fr unknown
- 1999-08-11 US US09/372,352 patent/US20020151572A1/en not_active Abandoned
- 1999-08-11 CO CO99051077A patent/CO5130011A1/es unknown
-
2001
- 2001-01-16 IS IS5814A patent/IS5814A/is unknown
- 2001-02-06 CR CR6302A patent/CR6302A/es not_active Application Discontinuation
- 2001-02-08 HR HR20010099A patent/HRP20010099A2/hr not_active Application Discontinuation
- 2001-02-09 NO NO20010685A patent/NO20010685L/no not_active Application Discontinuation
-
2002
- 2002-05-13 HK HK02103597.9A patent/HK1041819A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0203122A2 (hu) | Fab I inhibitorok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| DE68914292D1 (de) | Zusammensetzung zur Behandlung von ischämischen Störungen in Organen. | |
| GEP20053421B (en) | Substituted Pyrazoles As P38 Kinase Inhibitors, Method for Their Production and Pharmaceutical Compositions Containing Them | |
| LV12209A (lv) | Ar fenilgrupu aizvietoti heterocikli ka ciklooksigenazes-2 inhibitori | |
| ATE202076T1 (de) | Ester der 5-aminolevulinsäure als mittel zur photosensibilisierung in der chemotherapie | |
| CA2318349A1 (en) | Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use | |
| YU45403A (sh) | Novi 1,2-difenil-azetidinoni, postupak za njihovu proizvodnju, lekovi koji sadrže ova jedinjenja i njihova primena za lečenje poremećaja u metabolizmu lipida | |
| KR940005553A (ko) | N- 벤조일아미노산 유도체, 이를 함유하는 약제학적 조성물 및 이의 제조방법 | |
| ATE306261T1 (de) | Antithrombosemittel | |
| BR9510168A (pt) | Composto poliaminoácido composição forma unitária de dosagem e método par epreparar uma composição | |
| RU94038064A (ru) | Производные пиперазина и пиперидина, их применение в качестве противопсихотических средств, способ их получения фармацевтическая композиция | |
| ATE229017T1 (de) | Farnesyltransferase-inhibitoren mit piperidinstruktur und verfahren zu ihrer herstellung | |
| HUP9903336A2 (hu) | Szulfonsav-N-[(amino-imino-metil)-fenil]-aza-heretero-ciklil-amid származékok és az ezeket tartalmazó gyógyszerkészítmények | |
| ATE311188T1 (de) | Kombination eines angiotensin-ii antagonistisch wirkenden benzimidazols mit manidipin zur behandlung von bluthochdruck | |
| DK0453042T3 (da) | Hidtil ukendte 2 9-disubstituerede 4H-pyhrido[1 2-a]pyridin-4-oner | |
| ES2133324T3 (es) | Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y metodos de uso. | |
| NO307688B1 (no) | Anvendelse av terfenadinderivater som antihistaminmidler i et farmasøytisk preparat | |
| ATE268337T1 (de) | C11-carbamate von antibakteriellen makroliden | |
| FI944823A0 (fi) | Galantamiinijohdannaisia, menetelmä niiden valmistamiseksi ja niiden käyttö lääkeaineissa | |
| MD1560G2 (ro) | Compuşi ciclici, compoziţii farmaceutice pe baza lor şi metode de tratament al infecţiilor sau bolilor provocate de retrovirusuri | |
| FI874865A (fi) | Menetelmä lääkeaineena käyttökelpoisten imidatsolidinonijohdannaisten valmistamiseksi | |
| HUP0103113A2 (hu) | NOS inhibitorokat tartalmazó gyógyászati készítmények | |
| ATE19773T1 (de) | Nitroaliphatische verbindungen, verfahren zu deren herstellung und deren verwendung. | |
| MD502G2 (ro) | Derivaţi noi ai adenozinei, procedee de preparare a lor, compoziţii farmaceutice ce le conţin | |
| MD522G2 (ro) | Noi derivaţi de piperidinii tioindol, procedeu de preparare a lor, compoziţii farmaceutice care le conţin, utilizare a lor ca analgezice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |